WO2005101022A3 - Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1) - Google Patents

Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1) Download PDF

Info

Publication number
WO2005101022A3
WO2005101022A3 PCT/EP2005/003471 EP2005003471W WO2005101022A3 WO 2005101022 A3 WO2005101022 A3 WO 2005101022A3 EP 2005003471 W EP2005003471 W EP 2005003471W WO 2005101022 A3 WO2005101022 A3 WO 2005101022A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
vdr1
dihydroxyvitamin
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/003471
Other languages
French (fr)
Other versions
WO2005101022A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005101022A2 publication Critical patent/WO2005101022A2/en
Publication of WO2005101022A3 publication Critical patent/WO2005101022A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human VDR1 which is associated with the infections, cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, muscle skeleton disorders and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of infections cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological deiseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, muscle skeleton disorders and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of VDR1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/003471 2004-04-15 2005-04-02 Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1) WO2005101022A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04008924.5 2004-04-15
EP04008924 2004-04-15

Publications (2)

Publication Number Publication Date
WO2005101022A2 WO2005101022A2 (en) 2005-10-27
WO2005101022A3 true WO2005101022A3 (en) 2006-02-09

Family

ID=34966183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003471 WO2005101022A2 (en) 2004-04-15 2005-04-02 Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1)

Country Status (1)

Country Link
WO (1) WO2005101022A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
WO1999049027A1 (en) * 1998-03-25 1999-09-30 Cutanogen, Inc. Methods for prevention and treatment of cancer
WO2003041657A2 (en) * 2001-11-14 2003-05-22 Isis Pharmaceuticals, Inc. Antisense modulation of vitamin d nuclear receptor expression
US20030207810A1 (en) * 1996-12-30 2003-11-06 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
WO2004020379A1 (en) * 2002-08-27 2004-03-11 Galderma Research & Development, Snc Analogues of vitamin d

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207810A1 (en) * 1996-12-30 2003-11-06 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
WO1999049027A1 (en) * 1998-03-25 1999-09-30 Cutanogen, Inc. Methods for prevention and treatment of cancer
WO2003041657A2 (en) * 2001-11-14 2003-05-22 Isis Pharmaceuticals, Inc. Antisense modulation of vitamin d nuclear receptor expression
WO2004020379A1 (en) * 2002-08-27 2004-03-11 Galderma Research & Development, Snc Analogues of vitamin d

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONSOLINI R ET AL: "Effects of vitamin D on the growth of normal and malignant B-cell progenitors", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 126, no. 2, November 2001 (2001-11-01), pages 214 - 219, XP002346061 *
CSÁSZÁR A ET AL: "Receptor polymorphisms and diseases", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 414, no. 1, 2001, pages 9 - 22, XP002345953 *
MANFREDINI R ET AL: "Induction of a functional vitamin D receptor in all-trans-retinoic acid- induced monocytic differentiation of M2-type leukemic blast cells", CANCER RESEARCH, vol. 59, no. 15, 1 August 1999 (1999-08-01), pages 3803 - 3811, XP002346062 *
VOGEL ARNDT ET AL: "Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis", HEPATOLOGY, vol. 35, no. 1, 2002, pages 126 - 131, XP002345952 *

Also Published As

Publication number Publication date
WO2005101022A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2006008003A3 (en) Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2005101022A3 (en) Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase